<DOC>
	<DOCNO>NCT00917202</DOCNO>
	<brief_summary>Design : Single-centre , control study adult uncomplicated falciparum malaria Nouna Health District , north-western Burkina Faso Phase : Phase II Objectives : The primary objective trial study efficacy different methylene blue regimens give adult uncomplicated falciparum malaria African area high malaria transmission intensity . Population : Male adult uncomplicated malaria Nouna town . Sample size : N= 60 ( n=20 group ; three different dose regimen MB ) . Treatment : The participant three different MB regimen receive orally twice daily 390 mg MB ( total daily dose 780mg ) 7,5 3 day respectively . Treatment five ( three ) day regimen start patient seven ( five ) day regimen follow day 3 . Endpoints : The primary endpoint adequate clinical parasitological response ( ACPR ) rate day 28 . Secondary endpoint number adverse event ( AE ) drug intake day 28 , clinical parasitological failure rate day 14 28 , change haemoglobin/haematocrit day 28 , fever parasite clearance time .</brief_summary>
	<brief_title>Efficacy Methylene Blue Malaria Treatment Adults Burkina Faso : Proof Principle Study Semi-Immune Adults Burkina Faso Frame A8 Project SFB 544</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Male adult ( &gt; 17 year ; &lt; 55 year ) Uncomplicated malaria cause P. falciparum Asexual parasites ≥ 1000/µl ≤ 200 000/µl Axillary temperature ≥ 37.5°C history fever 48 hour Living nouna Health District Informed consent Complicated severe malaria Any apparent significant disease Anaemia ( haematocrit &lt; 21 % ) Antimalarial treatment prior inclusion ( last three day ) Increased creatinine blood level</criteria>
	<gender>Male</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>